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Massive transcriptome sequencing 
of human spinal cord tissues 
provides new insights into motor 
neuron degeneration in ALS
Anna Maria D’Erchia1,2, Angela Gallo3, Caterina Manzari2, Susanna Raho3, David S. Horner5, 
Matteo Chiara2, Alessio Valletti  2, Italia Aiello2, Francesca Mastropasqua1, Loredana 
Ciaccia1, Franco Locatelli3, Francesco Pisani1, Grazia Paola Nicchia1, Maria Svelto1,4,6, 
Graziano Pesole  1,2,4,6 & Ernesto Picardi  1,2,4
ALS is a devastating and debilitating human disease characterized by the progressive death of upper 
and lower motor neurons. Although much effort has been made to elucidate molecular determinants 
underlying the onset and progression of the disorder, the causes of ALS remain largely unknown. In 
the present work, we have deeply sequenced whole transcriptome from spinal cord ventral horns of 
post-mortem ALS human donors affected by the sporadic form of the disease (which comprises ~90% 
of the cases but which is less investigated than the inherited form of the disease). We observe 1160 
deregulated genes including 18 miRNAs and show that down regulated genes are mainly of neuronal 
derivation while up regulated genes have glial origin and tend to be involved in neuroinflammation or 
cell death. Remarkably, we find strong deregulation of SNAP25 and STX1B at both mRNA and protein 
levels suggesting impaired synaptic function through SNAP25 reduction as a possible cause of calcium 
elevation and glutamate excitotoxicity. We also note aberrant alternative splicing but not disrupted 
RNA editing.
Amyotrophic lateral sclerosis (ALS) is a fatal and devastating neurodegenerative disorder that causes the pro-
gressive death of upper and lower motor neurons1. Symptoms and clinical signs, including muscle weakness and 
atrophy, fasciculations, hyperreflexia, dysarthria and dysphagia emerge when axonal connections fail, leading to 
denervation1. The worldwide incidence of ALS is approximately two per 100,000 individuals and the mean age of 
onset is 55–60 years, with a higher incidence among men than women1.
The vast majority of documented cases are sporadic (~90%), without any associated family history. Sporadic 
and inherited (usually through an autosomal dominant pattern) forms of ALS show common clinical and patho-
logical traits, suggesting equivalent pathogenic mechanisms1.
Although much effort has been done in elucidating molecular factors underlying the onset and progression 
of the disorder, the causes of ALS remain unknown2. However, numerous investigations in humans and animal 
models have associated nucleotide variants in a small group of genes (including SOD1, UBQLN2, VCP, OPTN, 
TDP43, FUS, MATR3 and a hexanucleotide repeat expansion within c9orf72) with the familial form of ALS2.
Microarray-based transcriptome studies have revealed multiple perturbations of motor neuron function 
in both forms of ALS3, 4, consistent with the hypothesis that various cellular events, including mitochondrial 
dysfunction, enhanced apoptosis, glutamate-mediated excitotoxicity, free radical injury, protein misfolding, 
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abnormal calcium metabolism, altered axonal transport and activation of proteases and nucleases contribute to 
the pathobiology of the disease5.
Since motor neurons cannot be sampled during life, investigations into ALS neurodegenerative process are 
carried out in neuronal-like cells in culture, animal models carrying mutant transgenes or post-mortem material 
from patients. In the last case, the spinal cord represents the elective tissue and a pivotal source of RNA for gene 
expression profiling in ALS. While mixed cell populations in which astrocytes, microglia and oligodendrocytes 
may obscure the distinctive expression profile of motor neurons, which are the most affected in ALS, the co-culture 
of motor neurons and glial cells has shown an intricate interplay, suggesting that non-neuronal cells play an active 
role in neurodegeneration6. Accordingly, transcriptomic studies using high throughput sequencing approaches 
(RNA-Seq) to target specific tissues, such as ventral horns of the spinal cord, may provide new insights into genes 
and pathways involved in the degeneration of motor neurons. Indeed, RNA-Seq allows more accurate and com-
plete expression profiling than classical microarrays, overcoming their reliance on pre-designed probes. Recently, 
two studies exploring transcriptome alterations in ALS by the RNAseq technology have been reported7, 8. The 
first one investigated transcriptome changes in cerebellum and frontal cortex from familiar (fALS) (with mutated 
c9orf72 gene) and sporadic ALS (sALS) donors, showing extensive dysregulation of alternative splicing and alter-
native polyadenylation in both ALS groups7. The second one, based on RNAseq technology, investigated transcrip-
tome changes in cervical spinal cord tissues from sALS donors showing that neuroinflammation mediated by TNF 
(tumor necrosis factor) is the main transcriptome abnormality in sALS8.
In the current work, we also report the analysis of whole transcriptome sequencing data from matched control 
and sALS post-mortem donors but, differently from previous studies, we focus on the detection and character-
ization of significant changes in ventral horns of the human lumbar spinal cord, a tissue never investigated at 
single nucleotide resolution. While massive sequencing of the low molecular weight RNA fraction showed 18 
dysregulated miRNAs involved in TGF-beta signaling, axon survival and outgrowth, RNA-Seq data revealed 
altered expression of 1142 genes belonging to a restricted range of ALS deregulated molecular pathways including 
an impaired synaptic function. In particular, we focused our attention on two downregulated neuronal t-SNARE 
proteins, SNAP25 and Syntaxin-1B (STX1B), as they form with the v-SNARE protein synaptobrevin, a ternary 
complex mediating the neurotransmitter release at the presynaptic membrane. Notably, SNAP25 negatively reg-
ulates native voltage-gated calcium channels (VGCCs) in glutamatergic neurons9, and its reduced expression 
enhances glutamatergic neurotransmission10 and causes neurodegeneration11.
Taken together, our results may represent a remarkable breakthrough to unveil sALS, supporting a primary 
role of t-SNARE protein expression as possible cause of intracellular calcium elevation and glutamate excitotox-
icity12 and suggesting SNAP25 and related SNARE proteins as candidate novel indicators and signatures of motor 
neuron death to be monitored in ALS patients.
Results
RNA-Seq data analysis. Our study includes ventral horns of the lumbar spinal cord from six human donors 
affected by sporadic ALS and five age, sex and ethnicity matched controls (Table 1). ALS and control transcrip-
tomes were sequenced employing the Illumina technology on the NextSeq 500 platform. We generated 1.9 billion 
100 bp strand-specific paired end reads with, on average, 179 million pairs of reads per sample (Table 2). About 
73% of these reads were uniquely aligned to the reference human genome (hg19 assembly) after a cleaning step 
to remove low quality regions (Table 2). Using RefSeq annotations we verified that about 98% of mapped reads 
maintained the correct strand orientation and, on average, 46% of mapped bases corresponded to UTR and cod-
ing regions of known mRNA transcripts (Table 2).
To confirm the sporadic disease nature of our samples, we checked for the presence of known ALS mutations 
in aligned RNAseq data using REDItools13 and did not find any potentially fALS- associated variant in the causa-
tive genes annotated in the ALS Online Genetic Database (ALSoD http://alsod.iop.kcl.ac.uk/)14.
We calculated RNAseq based gene expression levels in FPKM and performed unsupervised hierarchical clus-
tering to detect similarities in gene expression profiles between ALS and control samples. We observed a clear 
separation between diseased and normal groups, suggesting specific transcriptome signatures for ALS (Fig. 1A). 
Principal component analysis (PCA) of variant genes re-marked such separation (Fig. 1B).
Using cell type specific genes for neurons, motorneurons, astrocytes, oligodendrocytes and microglia collected 
from the literature6, 15, we verified the cell type composition of our spinal cord samples (Fig. 2 and Supplementary 
Table 1). Interestingly, we found statistically significant changes in cell populations composed by neurons, motor-
neurons, oligodendrocytes and microglia. No substantial differences were detected in the astrocyte population 
(Fig. 2). While neuron, motorneuron and oligodendrocyte populations appeared depleted in ALS samples, micro-
glial population was over-represented suggesting neuroinflammation, that is thought to be critically important in 
the neurodegenerative process16 (Fig. 2).
Differentially expressed genes in ALS and controls. Differential gene expression between ALS and 
control samples was performed using only unique and concordant RNA-Seq reads. To improve the computational 
detection of differentially expressed (DE) genes, we applied two independent tools: CuffDiff2 based on FPKM 
metric that accounts for both uncertainty resulting from read mapping ambiguity and cross-replicate variabil-
ity17, and DESeq2 based on counts of reads in genes18. The final list of DE genes was selected by the intersection 
between CuffDiff2 and DEseq2 lists of significant DE genes and taking into account only genes with |log2(FC)| 
higher than 1. On the whole, we identified 1142 deregulated genes, for some of them a specific cellular origin is 
known from the literature (Supplementary Table 2), with log2(FC) values highly correlated between CuffDiff2 
and DEseq2 (Pearson r = 0.98) (Fig. 3 and Supplementary Table 2). Of these, 559 (49%) were upregulated in ALS 
samples and mainly involved in neuroinflammation or activation of immune response (Fig. 4, Supplementary 
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Table 3). Fifty-seven upregulated genes were also found deregulated in a previous study based on peripheral blood 
of ALS patients19 and, thus, they may represent a precious source of potential biomarkers.
Downregulated genes account for the 51% (583) of all DE genes and were significantly enriched (P ≪ 10−4 
hypergeometric test) in neuronal-specific genes (Fig. 4 and Supplementary Tables 4 and 5). Consistent with 
past investigations, down expressed genes were involved in several biological processes of nervous system as 
impulse transmission (SLC1A2, CHAT, SLC12A5, HTR2C) or synapse function (SNPH, SYT4, SNAP25, 
STX1B) or calcium metabolism (GRIN1, GRIN2A, CACNA1G) (Fig. 4 and Supplementary Tables 2 and 4). 
RNA-Seq analysis revealed also downregulation of key enzymes in cholesterol biosynthesis including HMGCR 
(3-hydroxy-3-methylglutaryl-CoA reductase), HMGCS1 (3-hydroxy-3-methylglutaryl-CoA synthase 1), 
Bank ID BID Age Sex Race Diagnosis PMI RNA-Seq miRNA-Seq
qRT-
PCR WB IF
NICHD A1 5388 61 M Ca sALS 8 ✓
NICHD A2 925 54 M Ca sALS 3 ✓
NICHD A3 4762 59 M Ca sALS 6 ✓
NICHD A4 5595 56 M Ca sALS 16 ✓ ✓ ✓ ✓
NICHD A5 1292 45 M Ca sALS 15 ✓ ✓ ✓ ✓ ✓
HBSFRC A6 5215 59 M Ca sALS 12,5 ✓ ✓ ✓ ✓
HBSFRC A7 5187 69 M Ca sALS 13,1 ✓ ✓ ✓ ✓
HBSFRC A8 5165 55 M Ca sALS 18,3 ✓ ✓ ✓ ✓ ✓
HBSFRC A9 5223 47 M Ca sALS 16 ✓ ✓ ✓
HBSFRC A10 5216 53 M Ca sALS 16,8 ✓ ✓ ✓
NICHD A11 5678 55 M Ca sALS 6 ✓
NICHD H1 5456 57 M Ca ACD 16 ✓ ✓ ✓ ✓ ✓
NICHD H2 5663 42 M Ca UK 16 ✓ ✓ ✓ ✓
NICHD H3 5458 64 M Ca MI 13 ✓ ✓ ✓ ✓
NICHD H4 5361 42 M Ca CT 19 ✓ ✓ ✓ ✓ ✓
NICHD H5 5617 59 M Ca MI 10 ✓ ✓ ✓ ✓ ✓
NICHD H6 5393 56 M Ca ACD 22 ✓
NICHD H7 5353 43 M Ca CD 9 ✓ ✓ ✓
Table 1. Control and ALS samples used in this study. For each sample we report: Bank (Tissue bank: NICHD or 
HBSFRC), ID (Sample ID used in the manuscript, Figures and Tables), BID (unique Bank ID from tissue bank), 
age, sex, race (Ca = Caucasian), main diagnosis (sALS = Sporadic ALS; ACD = Atherosclerosis Cardiovascular 
Disease; HEM = Hemopericardium; UK = Unknown; CD = Combined Drugs; MI = Multiple injuries; 
CT = Cardiac tamponade), post-mortem delay (in hours), flags indicating if the sample has been assayed for 
RNA-Seq, miRNA-Seq, qRT-PCR, immunoblotting (WB) or immunofluorescence (IF).
ID #FR #CFR #AFR % AFR % RB % COD % UTR % INTR % INTER % MRNA % COR_STR
A4 54680251 45068732 40934057 90,83 1,00E-06 0,153 0,135 0,433 0,279 0,288 0,972
A5 85144930 66912832 58474545 87,39 2,00E-06 0,217 0,162 0,440 0,182 0,378 0,984
A6 76440384 61373970 53373122 86,96 2,00E-06 0,277 0,210 0,386 0,127 0,487 0,992
A7 83340776 74094106 64311655 86,80 2,00E-06 0,292 0,226 0,347 0,134 0,518 0,993
A8 74664234 55858789 48680941 87,15 2,00E-06 0,299 0,219 0,358 0,123 0,519 0,993
A9 96273069 85995872 75818167 88,16 2,00E-06 0,234 0,203 0,428 0,135 0,437 0,990
H1 109502733 88454014 77268812 87,35 2,00E-06 0,237 0,197 0,432 0,133 0,434 0,990
H2 106819322 91146575 80112958 87,89 2,00E-06 0,243 0,193 0,423 0,142 0,435 0,989
H3 103962426 88206006 77528076 87,89 2,00E-06 0,302 0,233 0,342 0,122 0,536 0,993
H4 92670547 81318295 73329651 90,18 1,00E-06 0,297 0,230 0,338 0,134 0,528 0,992
H5 101742727 79106426 69660162 88,06 2,00E-06 0,267 0,216 0,384 0,133 0,483 0,992
Mean 89567400 74321420 65408377 88,06 1,82E-06 0,256 0,202 0,392 0,149 0,459 0,989
Table 2. Main statistics for RNA sequencing. Here we report main statistics about RNA sequencing calculated 
by in house python scripts and Picard tools. RefSeq gene annotations were downloaded from UCSC genome 
browser. Column headers are: ID (Unique Sample ID); #FR (Number of sequenced Fragments); #CFR (Number 
of cleaned Fragments); #AFR (Number of uniquely aligned Fragments); % AFR (Fraction of uniquely aligned 
Fragments); % RB (Fraction of Ribosomal Bases); % COD (Fraction of Protein Coding Bases); % UTR (Fraction 
of UTR Bases); % INTR (Fraction of Intronic Bases); % INTER (Fraction of Intergenic Bases); % MRNA 
(Fraction of mRNA Bases); % COR_STR (Fraction of Fragments in the correct orientation). The effective 
number of sequenced read is equal to the double of the number of fragments.
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MSMO1 (methylsterol monooxygenase 1) and SQLE (squalene epoxidase), which may affect the organization 
of cellular membranes and, in turn, modify axon guidance and synaptic transmission (Fig. 4 and Supplementary 
Tables 2 and 4).
Within the group of down-regulated genes we found a set of 15 synaptic proteins related to the synaptic vesicle 
cycle (P ≪ 0.0001 hypergeometric test) that consists of docking and fusion of the vesicles, and subsequent exocy-
tosis and neurotransmission (Table 3). Changes in synaptic transmission have been investigated in Alzheimer’s 
disease20 and may have a primary role in ALS for which little is known. Our results indicate deregulation of key 
genes for synaptic function including the two neuronal t-SNARE proteins, SNAP25 and STX1B. Recent evidence 
suggests novel functions for SNAP25 in controlling calcium dynamics and enhancing glutamate release in neu-
rons9, 10, consistent with a role for SNAP25 in ALS pathogenesis.
SLC1A2 which encodes a glutamate transporter essential for terminating the postsynaptic action through the 
glutamate clearance, appeared negatively regulated in ALS. This finding was also consistent with previous inves-
tigations showing down regulation of human SLC1A2 protein in ALS spinal cord21.
Fourteen out of 126 genes associated with ALS (mostly by mutation or GWAS studies) from the specialized 
ALSoD database14 showed differential expression in our ALS samples, 10 were down-regulated (including PRPH, 
UNC13A, SLC1A2, SNCG and NEFH) and 4 were up-regulated (SOD2, APOE, LOX and RNASE2).
Mitochondrial dysfunction is common in ALS pathogenesis since mitochondria have a central role in intracel-
lular energy production, calcium homeostasis and control of apoptosis22. Indeed, we found several differentially 
expressed genes correlated with mitochondrial functions. However, the expression levels of genes transcribed by 
Figure 1. Hierarchical clustering and PCA analysis of RNAseq data. (A) Hierarchical clustering conducted on 
CuffDiff2 expression values (in FPKM). ALS and control samples are clearly separated in two distinct groups. 
(B) PCA analysis of variant genes in which input samples are clustered in diseased (red circles) and normal 
(blue circles) groups.
Figure 2. Cell type composition analysis of human spinal cord samples. For each cell type we show the 
geometric mean of the FPKM values of the cell type marker genes (Supplementary Table 1). Statistically 
different cell type composition is calculated by Mann-Whitney U test (two-tails). *P < 0.05; **P < 0.01; −Not 
significant.
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the mitochondrial genome were unchanged, indicating that mitochondrial transcription may not be impaired in 
ALS (Supplementary Table 6). Nonetheless, mutations in the mitochondrial genome may occur due to oxidative 
stress - a hallmark of motor neuron injury22.
Pathway analyses. Differentially expressed genes were further analyzed through the IPA tool (Ingenuity® 
Pathway Analysis, www.ingenuity.com) in order to identify the most significantly up-regulated and 
down-regulated canonical pathways associated to neurodegeneration in ALS.
Consistent with other transcriptome investigations in transgenic SOD1 mice and human samples, the most 
highly activated pathways were related to neuroinflammation and immune response (Fig. 5 and Supplementary 
Table 7). Indeed, our dataset included many up-regulated genes encoding inflammatory mediators such as 
chemokines and interleukins and several components of the complement system, oncostatin M signaling and 
STAT3 pathways (Supplementary Table 7).
Significantly down-regulated pathways, instead, included cholesterol biosynthesis, calcium signaling, glu-
tamate receptor signaling and GABA receptor signaling (Fig. 5 and Supplementary Table 7). In addition, sev-
eral under expressed genes in ALS samples were associated with neurological and neurodegenerative human 
disorders such as bipolar disorder, schizophrenia, Huntington’s disease or Alzheimer’s disease (Supplementary 
Table 8). IPA analysis revealed also a significant enrichment for amyotrophic lateral sclerosis signaling, involving 
nine genes encoding mainly for calcium channels and glutamate receptors (Supplementary Table 8).
Our results were further corroborated by GO-PCA software implementing an unsupervised method to 
explore gene expression data using prior knowledge in the form of gene ontology (GO) annotations23. GO-PCA 
is able to detect specific signatures, consisting of small set of genes that are strongly correlated by their expression 
as well as functionally related by GO annotations23.
Figure 3. Gene expression analysis of ALS and controls samples using RNAseq. (A) Correlation between 
log2(FC) values of differently expressed genes detected by CuffDiff2 and DEseq2 (Pearson r = 0.98). (B) Heat 
map of 1142 genes differentially expressed between ALS and control samples. Color bars above the heat map 
indicate the disease status: red, ALS; blue, control. Each row of the heat map represents the Z-score transformed 
FPKM values of one differentially expressed gene across all samples.
www.nature.com/scientificreports/
6SCIENtIfIC REPORtS | 7: 10046  | DOI:10.1038/s41598-017-10488-7
We found 10 significant signatures (P ≪ 0.001) containing between 5 and 10 genes (Table 4). Five signatures, 
including down-regulated genes, were derived from GO terms related to cholesterol biosynthesis, glutamate 
secretion, motor activity or axon functionality (Table 4). Remaining five signatures, instead, were associated to 
inflammation and comprised up-regulated genes (Table 4).
Figure 4. Gene Ontology (GO) analysis of differentially expressed genes. Diagram of GO (Biological Process) 
terms that are significantly enriched in differentially expressed genes. Categories in the upper part of the figure 
are enriched in down regulated genes in ALS. Categories in lower part of the figure are enriched in up regulated 
genes in ALS. The Enrich combined score is reported for each category66.
Gene
CuffDiff2 DESeq2
CTRL ALS log2(fc) pvalue padj log2(fc) pvalue padj
CACNA1B 4,755 2,003 −1,247 5E-05 0,00071 −1,070 0,00013 0,00175
CPLX1 33,535 5,542 −2,597 5E-05 0,00071 −2,111 0,00000 0,00000
CPLX2 26,962 6,223 −2,115 5E-05 0,00071 −1,528 0,00064 0,00611
DNM1 32,800 7,355 −2,157 7E-04 0,00650 −1,614 0,00007 0,00116
NSF 26,828 8,603 −1,641 5E-05 0,00071 −1,379 0,00016 0,00208
RAB3A 33,164 6,083 −2,447 5E-05 0,00071 −1,849 0,00001 0,00027
RIMS1 11,579 3,910 −1,566 5E-05 0,00071 −1,408 0,00000 0,00000
SLC17A6 4,820 1,057 −2,190 5E-05 0,00071 −1,432 0,00261 0,01776
SLC18A3 17,019 1,829 −3,218 5E-05 0,00071 −2,409 0,00000 0,00000
SLC32A1 6,263 1,280 −2,290 5E-05 0,00071 −1,674 0,00015 0,00197
SNAP25 232,315 36,663 −2,664 5E-05 0,00071 −1,741 0,00031 0,00352
STX1B 20,025 4,881 −2,037 5E-05 0,00071 −1,665 0,00002 0,00032
STXBP1 42,523 16,587 −1,358 5E-05 0,00071 −1,225 0,00001 0,00025
UNC13A 3,875 1,350 −1,521 5E-05 0,00071 −1,318 0,00000 0,00002
UNC13C 5,286 2,190 −1,271 5E-05 0,00071 −1,187 0,00000 0,00012
Table 3. DE genes linked to synaptic function. List of DE genes linked to synaptic function. Per each gene we 
report: gene name, mean expression levels (in FPKM) in control and ALS groups (from CuffDiff2), log2(fc), 
P-value and corrected P-value calculated by CuffDiff2 and log2(fc), P-value and corrected P-value calculated by 
DESeq2.
www.nature.com/scientificreports/
7SCIENtIfIC REPORtS | 7: 10046  | DOI:10.1038/s41598-017-10488-7
qRT-PCR validation. We validated RNA-Seq results performing quantitative Reverse Transcription PCR 
(qRT-PCR) assay using RNA extracted from the ventral horns of the lumbar spinal cord in an enlarged sample 
group (Table 1). We included donors assayed by RNA-Seq (5 controls and 6 ALSs) and an independent group of 2 
controls and 3 ALSs (Table 1). From the list of differentially expressed genes, we selected 16 candidates including 
genes known to be deregulated in ALS such as INA, HECW1 and SLC1A2 (representing a sort of internal con-
trol) and genes not yet described as altered in ALS but associated to significantly disrupted pathways such as the 
cholesterol biosynthesis, the complement system or the synaptic transmission (Table 5). All genes belonging to 
deregulated pathways were randomly selected (with |log2FC| ≥ 1), except for SNAP25 and STX1B involved in the 
t-SNARE complex mediating the neurotransmitter release at the presynaptic membrane.
Figure 5. Pathway analysis of differentially expressed genes. IPA pathways that are significantly enriched in 
differentially expressed genes. Pathways in the upper part of the figure are enriched in down regulated genes in 
ALS. Pathways in the lower part of the figure are enriched in up regulated genes in ALS. The ratio between the 
number of differentially expressed genes and the number of genes in the specific pathway is reported on x axis.
Label Status Gene set ID P-value
Median 
correlation Genes
MF: motor activity [5/5] UP GO:0003774 0,0000012 0,98 DYNC1I1, KIF3A, KIF3C, KIF5A, KIF5C
CC: microtubule [7/10] UP GO:0005874 0,0000073 0,99 KCNAB2, KIF3A, MAPRE3, REEP2, TUBA4A, TUBB2A, TUBB3
BP: glutamate secretion [5/8] UP GO:0014047 0,00016 0,96 CPLX1, RAB3A, SLC1A2, SNAP25, STXBP1
BP: cholesterol biosynthetic 
process [7/10] UP GO:0006695 0,000026 0,92
ACLY, CYP51A1, DHCR24, HMGCS1, IDI1, 
MSMO1, SQLE
CC: axon [10/21] UP GO:0030424 0,0001 0,99 CPNE6, EPB41L3, KCNA1, KCNAB2, NEFH, NEFL, NEFM, PTPRN, RAB3A, SCN1B
BP: neg. regulation of viral 
process [5/8] DW GO:0048525 0,0000011 0,43 FBLN1, IFITM1, IFITM2, IFITM3, SLPI
CC: blood microparticle [8/16] DW GO:0072562 3,9E-09 0,7 ANGPTL4, APOE, C1QB, C1QC, C3, CP, SERPINA3, STOM
BP: reactive oxygen species 
metabolic process [6/9] DW GO:0072593 0,000013 0,49 CYBA, CYBB, GPX1, GPX3, PDK4, SOD2
BP: receptor-mediated 
endocytosis [5/17] DW GO:0006898 0,00042 0,82 APOE, CD163, FCER1G, ITGB2, MSR1
BP: pos. regulation of 
inflammatory response [6/10] DW GO:0050729 0,00061 0,7
HYAL2, OSMR, S100A9, TLR2, TNFRSF1A, 
VAMP8
Table 4. GO-PCA analysis. Significant GO signatures detected by GO-PCA tool.
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The qRT-PCR analysis confirmed the differential expression emerged in RNA-seq analyses for all 16 genes 
(Fig. 6A) and the estimates of fold change in expression level were highly consistent with those from RNA-Seq 
(r = 0.98, P = 8.3 × 10−11 for CuffDiff2 and r = 0.96, P = 4.2 × 10−9 for DESeq2) (Fig. 6B).
Aberrant Alternative Splicing. RNA-Seq read alignments were further investigated to identify differential 
splicing between control and ALS samples. Using MATS24, a software tools implementing Bayesian multivariate 
analysis of transcript splicing, we discovered 794 aberrant splicing events (Table 6). Of these, 98% involved exon 
skipping (including mutually exclusive exons) and 2% altered donor or acceptor splice sites and intron retention 
(Table 6).
IPA analysis of gene targets for differential splicing revealed perturbations in genes with important neuronal 
functions (Supplementary Table 9). In particular, we found genes involved in the actin cytoskeleton signaling, 
which plays central roles in dynamic processes such as cell motility or axon guidance. GNRH signaling, which 
coordinates the levels of hormones in the hypothalamic-pituitary-gonadal axis and promotes the activation of 
G-Proteins, PLC, PKC or the mobilization and influx of calcium was also enriched in genes showing differential 
splicing as well as genes involved in triacylglycerol biosynthesis and mitochondrial functions (Supplementary 
Table 9).
Twenty-one of the genes exhibiting differential exon skipping were previously identified in an exon array 
analysis of motorneurons in sporadic ALS samples25.
Gene Ontology terms highly enriched in differentially spliced genes included: axon guidance, neuron projec-
tion guidance, anchoring junction and actin binding (Supplementary Table 10).
miRNA-Seq analysis. An emerging hallmark of neurodegenerative diseases is the defective RNA metabo-
lism. It involves aberrant alternative splicing as demonstrated also by our RNA-Seq results and deregulated gene 
expression due to malfunction of miRNA activity26. Several previous investigations have documented a crucial 
role of miRNA gene regulation in the development and function of neurons. Consequently, alterations in the 
function of miRNA may contribute to neurodegenerative processes. Indeed, specific miRNA alterations have 
been reported for ALS microglia27 and affecting the stability of the low molecular weight neurofilament mRNA28.
We performed massive sequencing of the low molecular weight RNA fraction extracted from the same control 
and ALS donor tissues using in the RNA-seq analysis. Between 2.8 and 4.2 million reads were generated per sam-
ple and adaptors were removed using a custom script (adapters were detected in between 94.7–95.7% of reads for 
each sample) (Supplementary Figure 1). Reads were mapped to the human genome and miRNAs (reads mapping 
perfectly to annotated miRNAs and miRNA* were counted and assigned to non-redundant annotated miRNA 
sequences).
The vast majority of reads in the peak from 30–34 nt in length corresponded to the 5′ portions of annotated 
tRNA genes (consistently from nt1 to the anticodon loop) as observed previously29. The peak at 18 nt was com-
prised, predominantly (>95%), of tRNA derived small RNAs, almost exclusively consisting of few fragments 
Gene Symbol Description Assay ID
APOC1 apolipoprotein C-I Hs00155790_m1
ATP2B3 ATPase, Ca++ transporting, plasma membrane 3 Hs00222625_m1
CHD5 chromodomain helicase DNA binding protein 5 Hs01086457_m1
MYT1L myelin transcription factor 1-like Hs00903951_m1
STX1B syntaxin 1B Hs01041315_m1
SNAP25 synaptosomal-associated protein, 25 kDa Hs00938962_m1
CTSS cathepsin S Hs00175407_m1
SOD2 superoxide dismutase 2, mitochondrial Hs00167309_m1
SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 Hs01102423_m1
GPX3 glutathione peroxidase 3 Hs01078668_m1
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase Hs00168352_m1
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) Hs00940429_m1
INA internexin neuronal intermediate filament protein, alpha Hs00190771_m1
SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 Hs00153674_m1
HECW1 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 Hs00389648_m1
CD48 CD48 molecule Hs00914738_m1
GAPDH* glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1
HPRT1* hypoxanthine phosphoribosyltransferase 1 Hs99999909_m1
PGK1* phosphoglycerate kinase 1 Hs99999906_m1
POLR2A* polymerase (RNA) II (DNA directed) polypeptide A, 220 kDa Hs00172187_m1
Table 5. List of qRT-PCR validated genes and TaqMan Assay IDs. List of genes selected for qRT-PCR validation 
reporting the TaqMan Assay ID per gene symbol and the corresponding description. Genes indicated by * have 
been used as internal controls.
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representing positions 1–18 of tRNA-gly and tRNA-ala molecules. None of the aforementioned reads demon-
strated statistically significant differential expression between ALS patients and healthy controls.
The peak at 21 and 22 nucleotides was strongly enriched from known miRNAs that were subjected to differ-
ential expression analysis. After correction for multiple hypothesis testing, we found 18 dysregulated miRNAs 
(Padj ≤ 0.05) (Table 7). Of these, 3 were up-regulated and 15 down-regulated in ALS samples.
MiR-155 has previously been shown to be overexpressed in ALS microglial cells30 and inhibition of its expres-
sion has been shown to increase survival time in a murine ALS model31. MiR-485 has been implicated in synaptic 
formation and maintenance and has been reported to be dysregulated in Alzheimer’s disease and Huntington’s 
disease32, miR-124 is known as a neurodevelopmental regulator33, miR-219 required for neural precursor differ-
entiation in zebrafish34 and promotes myelination in rats35, miR-127 regulates cell proliferation and senescence 
Figure 6. Results from qRT-PCR validation. (A) Results from qRT-PCR validation of 16 selected DE genes 
(Table 3) in the input sample group of 6 controls and 5 Als patients (blue bars), and in an independent group 
of 2 controls and 3 Als (red bars). Up and down regulation are in respect to ALS donors. (B) Linear correlation 
between log2(FC) values computed by CuffDiff2 (blue circles) or DESEq2 (red circles) on RNA-Seq data and 
log2(FC) values detected by qRT-PCR for 16 selected genes.
Event Type N S
SE 72689 601
MXE 18275 178
A5SS 1004 5
A3SS 1205 2
RI 452 8
Total 93625 794
Table 6. Differential alternative splicing detected in RNA-Seq data by MATS program. For each alternative 
splicing type we repot the number of events in UCSC database (N) and the number of significant events (S). SE: 
skipped exon; MXE: mutually exclusive exon; A5SS: alternative 5′ splice site; A3SS: alternative 3′ splice site; RI: 
retained intron.
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by targeting BCL636 while miR-136, miR-873 and miR-410 have all been studied in the context of glioma growth, 
invasiveness and apoptosis37–39.
Uncertainties regarding both the reliability of target predictions and the extent of degradation of individual 
targeted mRNAs in vivo, as well as the mixed nature of the tissue samples complicate direct reconciliation of 
miRNA and putative target expression profiles. The Diana-miRPath tool40 recovered a striking set of 6 pathways 
(p ≤ 10−16) enriched in genes with predicted targets for differentially expressed miRNAs: the PI3K-Akt signal-
ing pathway, Axon guidance, Neurotrophin signaling pathway, Focal adhesion, TGF-beta signaling pathway and 
Insulin signaling pathway (Supplementary Table 11).
RNA editing analysis. To further characterize the transcriptome of ALS spinal cord samples, we inves-
tigated RNA editing limiting our search to A-to-I changes, as these account for over 99% of editing events in 
recent large-scale human investigations41, 42. In particular, for each RNA-Seq sample we explored known A-to-I 
events stored in the REDIportal database43, selecting only genomic positions supported by at least 30 reads and 
showing a RNA editing level higher than 0.1. Comparing positions in common between healthy and ALS donors, 
we found a strong correlation of 0,88 (Pval < 10e−14 by Spearman correlation test) in RNA editing levels. We also 
performed the non-metric multidimensional scaling (NMD) analysis on detected A-to-I changes in order to ver-
ify the grouping of input samples by RNA editing. Interestingly, we did not find specific ALS and control clusters 
as expected in case of global RNA editing alteration (Supplementary Figure 2), suggesting that it should not be 
impaired in ALS spinal cord tissues.
We observed reduction of RNA editing levels at the recoding GRIA2 Q/R site, known to be edited at nearly 
100% in human brain44 and under-edited in motor neurons of ALS donors and, thus, implicated in cell death by 
excitotoxicity45. However, reduced RNA editing levels at the recoding GRIA2 Q/R site were also observed in con-
trol samples and the difference between ALS and control groups was not significant (Mann-Whitney P = 0.43). 
Only one ALS sample showed strong A-to-I reduction level of 0.19 at GRIA2 Q/R site. Additionally, we compared 
our RNA editing levels of GRIA2 Q/R site with corresponding values from spinal cord and other brain loca-
tions of an independent group of healthy individuals from GTEx project and stored in our REDIportal database. 
Interestingly, GRIA2 Q/R site appeared highly edited in almost all brain locations (average editing levels from 
0.82 to 0.99), while editing levels of spinal cord samples (n = 15, average editing levels of 0.66) were quite similar 
to our values for both ALS (average editing levels of 0.62) and control (average editing levels of 0.66) groups, 
meaning that RNA editing levels at GRIA2 Q/R site are not always edited at nearly 100% in spinal cord (Fig. 7A 
and Supplementary Table 12). Editing frequencies of GRIA2 Q/R site in spinal cord samples were always signifi-
cantly lower than corresponding values from all tested brain locations (Mann-Whitney P < 0.05) (Table 8).
Further, we explored RNA editing in miRNAs employing massive sequencing of the low molecular weight 
RNA. We found 12 A-to-I changes in 12 miRNAs (Supplementary Table 13). Of these, 9 were known as edited in 
the literature, while 3 appeared as novel RNA editing events. All detected changes were observed in both control 
and diseased donors, even though RNA editing levels were not significantly different (Supplementary Table 13).
Finally, we explored expression values of ADAR genes but no significant differences were detected between 
healthy and ALS tissues (Fig. 7B).
miRNA log2FoldChange P-value
Corrected 
P-value
hsa-mir-577 −3,28 1,46E-10 3,87E-08
hsa-mir-182-5p −2,70 6,50E-15 3,44E-12
hsa-mir-485-5p −2,12 8,79E-05 8,45E-03
hsa-mir-124-3p −1,83 1,05E-05 1,85E-03
hsa-mir-218-5p −1,68 1,54E-04 1,16E-02
hsa-mir-183-5p −1,62 3,14E-04 2,08E-02
hsa-mir-873-5p −1,58 9,80E-04 3,25E-02
hsa-mir-133a −1,53 6,05E-04 2,29E-02
hsa-mir-487b −1,45 1,56E-03 4,59E-02
hsa-mir-219-5p −1,44 9,55E-04 3,25E-02
hsa-mir-409-3p −1,34 1,12E-03 3,48E-02
hsa-mir-889 −1,23 5,71E-04 2,29E-02
hsa-mir-136-3p −1,15 1,75E-03 4,87E-02
hsa-mir-410 −1,12 4,02E-04 2,29E-02
hsa-mir-127-3p −0,95 5,61E-04 2,29E-02
hsa-mir-148a-3p 1,23 4,99E-04 2,29E-02
hsa-mir-155-5p 1,82 9,56E-05 8,45E-03
hsa-mir-221-3p 2,10 4,82E-04 2,29E-02
Table 7. MiRNAs differentially expressed in healthy controls and ALS patients. For each differently expressed 
miRNA we report the standard name according to MirBase database, the log2 fold-change, the P-value and the 
corresponding corrected P-value as calculated by DESeq.
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Immunoblotting and Immunofluorescence of synaptic SNARE proteins in ventral horns of ALS 
donors. We corroborated our RNA-Seq and qRT-PCR results performing immunoblotting of two synaptic 
SNARE proteins, SNAP25 and STX1B, since they might provide new insights into neurotransmission and cal-
cium homeostasis alterations in ALS. Western blot analysis was performed on ventral horn of six patients with 
sporadic ALS and six controls to quantify the protein expression levels of SNAP25 and STX1B. Results obtained 
showed that SNAP25 and STX1B were significantly downregulated at protein level in ALS patients, in line with 
the mRNA data (Fig. 8 and Supplementary Figure 3). Since a functional redundancy between STX1B and its 
homologous STX1A has been reported46, STX1A protein expression levels were also analyzed in parallel. Results 
revealed an opposite trend for STX1 A being significantly upregulated in ALS patients (Fig. 8 and Supplementary 
Figure 3), as observed in FUS-silenced motor neurons47. Such upregulation appeared more prominent in five out 
of six ALS patients.
Additionally, we investigated in more detail the SNAP25 and STX1A deregulation by immunofluorescence 
followed by quantification analysis (Figs 9 and 10, Supplementary Figure 4) using confocal microscopy and β3 
tubulin as motor neuron marker. The intensity of SNAP25 and STX1A signal was normalized on the size of motor 
neuron cell body that we found to be reduced by almost 50% in ALS patients (Fig. 9B). In agreement with the 
SNARE-complex deregulation detected by Western blot (Fig. 8), we found that SNAP25 signal was almost com-
pletely absent in ALS patients (Fig. 9), whereas STX1A was significantly upregulated (Fig. 10).
Figure 7. RNA editing levels of GRIA2 Q/R site and the expression of ADAR genes. (A) RNA editing levels 
of GRIA2 Q/R site in spinal cord and other brain locations. Abbreviated body site names are as follow: SC, 
spinal cord; AM, Amygdala; ACC, Anterior cingulate cortex; CA, Caudate; CH, Cerebellar Hemisphere; CE, 
Cerebellum; CO, Cortex; FC, Frontal Cortex; HI, Hippocampus; HY, Hypothalamus; NAC, Nucleus accumbens; 
PU, Putamen; SN, Substantia nigra; SCC, Spinal cord control group; SCA, Spinal cord ALS group. (B) 
Expression levels of ADAR genes from RNA-Seq experiments using the Cuffdiff2 tool. FPKM values for controls 
and ALS donors are shown as box plots.
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Together, these results validate the RNA-Seq data on the altered expression pattern of genes in ALS and pro-
vide new information on the molecular basis of synapsis and calcium handling abnormalities associated with the 
motor neuron degeneration typical of this pathology.
Discussion
ALS is a rare and devastating neurodegenerative disease for which no effective therapies are available1. Large-scale 
genetic investigations, at least in the familial form of ALS, have identified several mutations in key genes for motor 
neuron survival2. Nonetheless, the causes of ALS onset and progression are yet elusive. Whole transcriptome 
SpinalCord BrainBodySites N. SC N. BodySites U-Stat Pval
SC ACC 15 22 56,5 0,00031
SC NAC 15 27 79,5 0,00057
SC CH 15 28 64,5 0,00007
SC CO 15 30 94,5 0,00085
SC PU 15 19 70,5 0,00647
SC CA 15 29 88 0,00058
SC AM 15 21 80,5 0,00699
SC CE 15 32 76,5 0,00007
SC FC 15 28 87,5 0,00073
SC HI 15 26 82 0,00098
SC SN 15 18 86,5 0,04087
SC HY 15 24 91 0,00513
SC SCC 15 5 35 0,43058
SC SCA 15 6 43 0,45344
Table 8. Comparison between editing frequencies at GRIA2 Q/R site in spinal cord and other brain locations. 
Statistical significance was assessed by Mann-Whitney U Test (U-Stat and Pval columns). N. SC indicates the 
number of samples in spinal cord from GTEx project, N. BodySites report the number of samples per each brain 
body site from GTEx project. Abbreviated body site names in BrainBodySites are as follow: SC, spinal cord; AM, 
Amygdala; ACC, Anterior cingulate cortex; CA, Caudate; CH, Cerebellar Hemisphere; CE, Cerebellum; CO, 
Cortex; FC, Frontal Cortex; HI, Hippocampus; HY, Hypothalamus; NAC, Nucleus accumbens; PU, Putamen; 
SN, Substantia nigra; SCC, Spinal cord control group; SCA, Spinal cord ALS group.
Figure 8. Immunoblot analysis of SNARE proteins in control (Ctrl) and ALS patient ventral horns. (A) Ventral 
horn samples were examined for STX1A, STX1B and SNAP25 expression by immunoblotting. GAPDH was 
used as internal control for protein loading. (B) Histograms summarizing the densitometry analysis of the 
protein bands shown in A, calculated as each SNARE/GAPDH expression ratio, as indicated (n = 6 for Ctrl and 
n = 6 for ALS; *P < 0.002). Samples are indicated by their Bank ID as reported in Table 1. The image in A was 
cropped for clarity from the original in Supplementary Figure 3.
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analyses have revealed the disruption of a variety of cellular pathways contributing to the elucidation of molecular 
dynamics characterizing the pathobiology of ALS3.
The main obstacle complicating ALS investigations is that motor neurons cannot be sampled during life. As 
a consequence, animal models and spinal cord tissue from post-mortem donors represent the elective materials 
for the study of gene expression in ALS. In humans, previous transcriptome studies have been conducted on laser 
microdissected motor neurons, in order to avoid biases from mixed cell populations. Although motor neurons 
are the most affected in ALS, other cell types such as astrocytes, microglia and oligodendrocytes may contribute 
to disease progression. Indeed, co-culture of motor neurons and glial cells has shown an intricate interplay and an 
active role of non-neuronal cells in neurodegeneration6.
In order to characterize whole transcriptome modifications occurring in sALS, we conducted a study in which 
total RNA from the lumbar spinal cord of ALS donors were sequenced using the RNA-Seq technology.
Our results demonstrate the suitability of deep transcriptome sequencing for capturing molecular changes in 
the lumbar spinal cord and provide new exciting insights still not revealed by recent whole transcriptome studies 
based on RNAseq in brain7 and cervical spinal cord8 from fALS and sALS samples.
Using a dataset of cell type-specific genes derived from various cell types in the CNS15 as astrocytes, oligo-
dendrocytes and neurons, our data show a depletion of neuron, motorneuron and oligodendrocyte populations 
with down regulated genes of neuronal derivation and linked to relevant neurological functions as impulse 
transmission, synaptic transmission, calcium ion transport or neurotransmitter secretion. Up regulated genes, 
instead, are generally involved in neuroinflammation, immune responses or cell death and tend to have micro-
glial origin.
RNA-Seq of ALS lumbar spinal cord therefore provides a snapshot of transcriptomic events characterizing 
the disease, suggesting that neuronal function is compromised through the down regulation of many genes. 
As a consequence of neurological injury, surrounding cells are activated leading to a cascade of inflammatory 
events. Although our data do not provide evidence regarding early molecular events causing the death of motor 
neurons, transcriptomic results would seem to support these speculations. In addition, comparing our results 
with those by Brohawn et al.8 in cervical spinal cord of sALS donors using similar technology and methodol-
ogy, it emerges that neuroinflammation is common in all sections of spinal cord but molecular signatures of 
neurodegeneration are more consistent in the lumbar rather than cervical spinal region. Our down regulated 
genes actually include genes already known to be associated to ALS motor neuron death such as INA, HECW1 
or SLC1A2.
As a remarkable result, RNA-Seq data support the down-regulation in ALS donors of SNAP25 and STX1B, 
neuronal t-SNAREs involved in vesicle trafficking and calcium dynamics. Since a redundant role between STX1B 
and its homologous STX1A has been reported48 and being STX1A the isoform interacting with SNAP25 and 
Figure 9. Confocal microscopy analysis of SNAP25 and β3-tubulin in spinal cord ventral horns of control 
and ALS patients. (A) Confocal microscopy images of SNAP25 (green) and β3-tubulin (red) of a typical motor 
neuron in control and ALS patient. (B,C) Histograms showing the motor neuron body size expressed in µm2 
(B) and the quantitative analysis of SNAP25 signal normalized on motor neuron size (C) of control and ALS 
patients (*P < 0.05). (D) Confocal 3D reconstruction of SNAP25 and β3-tubulin staining
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Voltage Gated Calcium Channels (VGCCs) to control calcium signaling, we have explored the t-SNARE pattern 
as a whole. In particular, we show that SNAP25 and STX1B are strongly downregulated also at protein level. 
STX1A, instead, was upregulated in five out of six ALS patients. Through immunofluorescence followed by quan-
tification analysis (Figs 9 and 10) using confocal microscopy and β3 tubulin as motor neuron marker, we confirm 
the deregulation of SNAP25 and STX1A in ALS patients and demonstrate that the down expression of SNAP25 is 
mainly due to the reduced size of motor neurons.
Ikemoto et al.49 have investigated SNAP25 and STX1 expression in ALS spinal cord finding no apparent 
decrease or only a mild reduction for both proteins in ALS patients. We believe that the immunolocalization 
approach performed in the study by Ikemoto49, without quantification analysis, has most likely led to an underes-
timation of the t-SNARE reduction in ALS patients. Moreover, the antibody used to detect STX1 was not isoform 
specific and therefore STX1 unaltered expression reported by Ikemoto49 is consistent with the data here reported 
where STX1A is upregulated and STX1B downregulated. Additionally, upregulation of STX1A and deregulation 
of SNAP25 splicing were observed also in FUS-silenced motor neurons47.
Experiments performed in animal models and primary cultures have shown that loss of SNAP25 impairs 
calcium-evoked exocytosis leaving almost unaffected spontaneous vesicle release50, 51 while deletion of STX1A 
has no effect on both types of synaptic transmission probably due to compensation by STX1B. Finally, STX1B 
deletion impairs both spontaneous and evoked fast synaptic vesicle exocytosis48.
According to our results on altered t-SNARE protein pattern, SNAP25 and STX1B reduction seem to strictly 
relate with the motor neuron dysfunction characteristics of ALS ventral horns in which STX1A up regulation may 
compensate for STX1B loss. Notably, the observed SNAP25 reduction highlights a potentially novel and relevant 
role of t-SNARE pattern in elevating intracellular calcium concentration and in triggering the glutamate excito-
toxicity. Indeed, SNAP25 silencing in glutamatergic neurons has been reported to increase the concentration of 
intracellular calcium evoked by depolarization52. Therefore an initial accident altering the t-SNARE pattern caus-
ing SNAP25 reduction should lead to the increased intracellular calcium levels found in ALS motorneurons12. 
In turn, elevated intracellular calcium concentration causes motor neuron injury leading to increased glutamate 
release and excitotoxicity. In this context, STX1A may compensate for SNAP25 reduction in order to restore 
calcium homeostasis.
Figure 10. Confocal microscopy analysis of STX1A and β3-tubulin in spinal cord ventral horn of control 
and ALS patients. (A) Confocal microscopy images of STX1A (green) and β3-tubulin (red) of a typical 
motor neuron in control and ALS patient. (B) Histograms showing the quantitative analysis of STX1A signal 
normalized on motor neuron size of control and ALS patients (*P < 0.05). (C) Confocal 3D reconstruction of 
STX1A and β3-tubulin staining.
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Another remarkable finding of our work is the dysregulation of cholesterol synthesis, which has been linked 
to chronic neurodegenerative disorders53. This alteration could contribute to the impaired axon guidance and 
synaptic transmission observed in ALS, as cholesterol is essential for the organization and physiological fluidity 
of cellular membranes.
RNA-Seq also confirms the disruption of RNA metabolism through aberrant alternative splicing potentially 
resulting from neuronal stress.
Additionally, we investigated RNA editing since its deregulation has been linked to several neurodegenerative 
diseases including ALS45. Indeed, it has been shown that reduced levels of recoding A-to-I editing at GRIA2 Q/R 
site may be involved in motor neuronal death through an increased Ca2+ permeability of AMPA receptor45. Our 
results, based on known RNA editing events, do not support significant alterations. A closer investigation of RNA 
editing levels at the recoding GRIA2 Q/R site reveals that A-to-I frequencies of GRIA2 Q/R site are not impaired 
in spinal cord tissue of ALS donors, rather their values are similar to those observed in physiological conditions 
without altered expression of ADAR enzymes. However, our study was conducted on entire tissues and, thus, 
we cannot exclude a compensating effect from non-neural cells obscuring specific motor neuron RNA editing 
alterations.
Small RNA expression analyses suggest important roles for miRNAs regulating signaling pathways determin-
ing cell survival and axon guidance during ALS progression. Numerous lines of evidence implicate TGF-beta 
signaling in motor neuron diseases. It participates in the interplay between neuronal and glial cells during ALS 
progression6 and increased levels of TGF-beta provoke an acute improvement in the motor performance of SOD1 
mice54. Participants in the TGF-beta signaling pathway predicted to be targets of DE miRNAs include Smad2,4,5 
and 7. TDP-43 and phosphorylated Smad2 are co-localized within cytoplasmic inclusions in the anterior horn 
cells of sporadic ALS patients55. Activation of the TGFβ/Smad signaling system is protective against aggregate 
formation of cytoplasmically mislocalized TDP-4355.
The Axon Guidance pathway has recently been proposed to represent a prime effector in ALS pathobiology56 
and is intimately linked to the regulation of actin cytoskeleton and Focal Adhesion circuits.
The phosphatidylinositol 3-kinase (PI3K) /ATK prosurvival pathway has been implicated as a mediator of the 
protective effect of vascular endothelial growth factor in G93A-SOD1 neurons in vitro and induction of ATK3 is 
neuroprotective in SOD1_G93A mice57. The pathway contributes, in conjunction with mTOR family proteins, to 
the regulation of the activity of the glutamate transporter GLT1 in astrocytes58.
Neurotrophins, including Nerve Growth Factor (NGF), brain-derived neurotrophic factor (BDNF), and 
Neurotrophins 3 and 4 (NTF3 and NTF4) lie upstream of the Neurotrophin pathway which regulates the axon 
cytoskeleton (and in turn axon outgrowth/guidance and synapse formation) as well as cell differentiation and 
survival. NFT3, NTF4, and BDNF, as well as their cellular receptors and numerous downstream genes are all pre-
dicted targets of miRNAs dysregulated in ALS. NGF, BDNF, NT-3 are neuroprotective on axotomized extraocular 
motoneurons in neonatal rats59, while 7,8-dihydroxyflavone (7,8-DHF) a small molecule tyrosine kinase receptor 
B (TrkB) agonist that mimics the effects of BDNF, is neuroprotective in SOD1 mice60.
In conclusion, our study remarks the use of massive RNA sequencing technologies to improve deregulated 
pathways of ALS neurodegeneration and provide new exiting insights as the SNAP25 reduction as possible cause 
of calcium elevation and glutamate excitotoxicity, suggesting t-SNARE protein expression as novel indicators and 
potential biomarkers for sporadic ALS.
Methods
Post mortem tissues. Frozen lumbar spinal cord samples from 11 male human donors affected by sporadic 
ALS and 7 age, sex and ethnicity matched controls were obtained from the NICHD Brain & Tissue Bank for 
Developmental Disorders (University of Maryland - http://medschool.umaryland.edu/btbank/) and the Human 
Brain and Spinal Fluid Resource Center (Los Angeles, CA). Additionally, we required as an additional criterion, 
the presence of clinical symptoms associated to the altered function of lower motor neurons.
Each tissue was longitudinally dissected and ventral horns were collected for downstream analyses.
Detailed information regarding samples used in RNA-seq, miRNA-seq, qRT-PCR and western blot analyses 
are provided in Table 1, also including age, gender, ethnicity and post-mortem interval as well as donor bank IDs 
to access to further clinical info.
RNA extraction. RNA was extracted from the ventral horns of the lumbar spinal cord after grinding with 
mortar and pestle using the mirVana™ miRNA Isolation Kits (Life Technologies Inc., Carlsbad, CA, USA) 
according to the manufacturer’s instructions to separate total and small RNA fractions. Each RNA sample was 
treated with RNAse-free DNAse (Life Technologies) and qualitatively and quantitatively checked on Agilent 2100 
Bioanalyzer RNA Nano Chip (Agilent, Santa Clara, CA, USA).
RNA sequencing. Directional RNA-Seq libraries were prepared from 1 μg of total RNA using the TruSeq 
Stranded Total RNA Sample Prep Kit (Illumina) according to the manufacturer’s protocol. Sequencing was per-
formed on an Illumina NextSeq 500 platform (Illumina, San Diego, CA), generating for each sample from 109 to 
219 millions of 100pb × 2 paired-end reads. RNA-Seq statistics are reported in Table 2.
miRNA sequencing. Indexed cDNA libraries from the RNA fraction at low molecular were prepared using 
the TruSeq small RNA sample Preparation kit (Illumina, San Diego, CA) according to the manufacturer’s protocol 
and recommendations. Single end sequencing (1 × 50b), after fluorimetric quantification, was performed on an 
Illumina Miseq platform.
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Preprocessing and analysis of RNA-Seq reads. RNA-Seq reads in FASTQ format were initially 
inspected using FASTQC program (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Adaptors and 
low quality regions (phred cutoff of 20) were trimmed using Trim Galore (http://www.bioinformatics.babraham.
ac.uk/projects/trim_galore/), excluding reads with final length less than 50 bases.
Cleaned reads were aligned onto the complete human genome (assembly hg19) by means of GSNAP61 version 
2013-11-27 (using as parameters: -B 5 -d hg19 -t5 -s splicesites -E1000 -N1 -n1 -Q -O-nofails -A sam–force-xs-dir 
-a paired) providing a list of exon-exon junctions from Ensembl, UCSC and RefSeq databases. Unique and con-
cordant alignments in SAM format were converted in the binary BAM format by SAMtools62 and basic statistics 
were calculated using the CollectRnaSeqMetrics tool of Picard package (https://broadinstitute.github.io/picard/
index.html) (Table 2). The sporadic disease nature of our samples was checked using REDItools13, screening 
known ALS mutations from ALSoD database in aligned RNAseq data14. Only positions showing a frequency 
variation higher than 0.1 and supported by more than 10 reads we taken into account.
Differential expression was performed using two independent tools: CuffDiff2 version 2.1.117 (using as 
main parameters:–library-type fr-firststrand–labels Ctl,Als -u -b hg19.fa refgenes.gtf) and DESeq2 version 
1.10.118. Read counts on known human genes were calculated by featureCounts version 1.5.163. Reference 
human transcriptome was obtained from iGenomes repository (http://cole-trapnell-lab.github.io/cufflinks/
igenome_table/) and annotations for rRNA genes were downloaded from UCSC genome browser selecting the 
RepeatMask table.
DE genes was selected intersecting lists of significant DE genes (corrected P value < 0.05) obtained by 
CuffDiff2 and DEseq2. We took into account only genes with |log2(FC)| higher than 1.
Changes in cell type composition of spinal cord samples was detected according to the method described in 
Lin et al.64 and using cell type specific genes for neurons, motorneurons, astrocytes, oligodendrocytes and micro-
glia collected from the literature6, 15. The majority of cell type specific genes were obtained from Cahoy et al.15 
taking into account only genes showing >10-fold enrichment in this study. Since Cahoy et al. performed their 
investigations in mouse, we selected only genes with corresponding human orthologues and showing FPKM 
values > 0. Motor neuron specific genes, instead, were collected from Phatnani et al.6.
Differential alternative splicing was detected with MATS version 3.0.924 using default parameters except 
for the read length (fixed to 90). Events were selected at 0.05 significant level, corrected for multiple testing. 
Heat-maps and PCA plots were generated using ClustVis65.
IPA system was used for pathway analysis. Enrich66, instead, was used to generate lists of Gene Ontology terms 
enriched in the upregulated, downregulated or differentially spliced gene lists, with default setting. To identify sets 
of genes that are both strongly correlated to expression data and functionally related to their GO annotations, we 
used the GO-PCA method23. In brief, it adopts a two-step approach in which PCA is performed first. Then, each 
principal component is tested for whether it is driven by functionally related genes (in the form of gene ontology 
annotations).
Preprocessing and analysis of miRNA-Seq reads. Raw sequence data were processed with a custom 
Python script to remove adapters from inserts of between 14 and 38 nt in length and subsequently mapped onto 
the human genome (version hg19) using Bowtie67. Counts of reads exactly matching human miRNAs and (where 
annotated in miRBase) miRNA* sequences were submitted to the DESeq software68 for statistical analysis of dif-
ferential expression using default parameters and treating different ALS and healthy control patients as biological 
replicates. Pathway analysis was conducted with miRPath v2.040 with default settings.
RNA editing detection and analysis. RNA editing candidates per each sample were detected using the 
REDItools package (https://sourceforge.net/projects/reditools/)13. In particular, REDItoolKnown.py was used to 
explore known RNA editing sites stored in REDIPortal database43. Non-Metric Multidimensional Scaling anal-
ysis of RNA editing sites was performed in R using the vegan package. RNA editing levels at the GRIA2 Q/R site 
in different brain regions were extracted from REDIportal43. Custom python scripts were used to calculate RNA 
editing correlation between control and ALS samples.
RNA editing detection in miRNAs was performed according to the protocol developed by Alon et al.69, while 
RNA editing levels were calculated by REDItools13.
qRT-PCR validation. Gene expression analyses were carried out on custom TaqMan Array Fast Plates (Life 
Technologies), configured in order to include four potential human endogenous control genes (GAPDH, HPRT1, 
PGK1 and POLR2A), and sixteen genes selected for validation (Table 5), each of them in duplicate per sample. 
Reverse transcription of 500 ng of total RNA was performed using “iScript Reverse Transcription Supermix for 
RT-qPCR” (Bio-Rad, Hercules, CA, USA). qPCR reactions were set up according to the manufacturer’s instruc-
tion of “TaqMan Fast Universal PCR Master Mix” kit (Life Technologies), starting from 1 µl of diluted cDNA (1:3) 
as template and performed using the ABI PRISM 7900HT platform (Applied Biosystem, Life Technologies) with 
the following amplification conditions: hot start at 95 °C for 10 min; 45 amplification cycles (95° for 15 sec, 60° 
for 1 min).
Control reverse transcription reactions (RT-) were also prepared and PCR reactions, using primers for HPRT1 
transcript (Forward: 5′-TGACACTGGCAAAACAATGCA-3′; Reverse: 5′-GGTCCTTTTCACCAGCAAGCT-3′), 
were carried out as control for genomic DNA contamination (data not shown).
Fluorescence raw data were exported from the SDS 2.2.1 software and analyzed using the comparative quan-
tification cycle (Cq) method to determine the relative ratio of transcripts. First, the ΔCt values were obtained 
by calculating, for each sample, the difference of the Cq of each target compared to the arithmetic mean of 
the endogenous Cq genes (GAPDH and HPRT1). Then, the relative expression ratio (rER) was expressed as 
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Log2(2−ΔCt); rER for each type of samples were averaged and calibrated respect to normal samples. Analyses were 
carried out using data related to two independent experiments.
Antibodies. The following primary antibodies were used: goat anti-SNAP25 (SC-7538, Santa Cruz, CA, 
USA), rabbit anti-Syntaxin-1A (110302, Synaptic System, Goettingen, Germany), rabbit anti-Syntaxin-1B 
(110402, Synaptic System, Goettingen, Germany), mouse anti-GAPDH (MAB 374, Millipore, Billerica, MA, 
USA) and mouse anti-β3 tubulin (SC-80016, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
The following secondary antibodies were used for Western blot: HorseRadishPeroxidase (HRP)-conjugated 
donkey anti-goat, goat anti-rabbit and goat anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
The following secondary antibodies were used for Immunofluorescence: donkey anti-rabbit and don-
key anti-goat AlexaFluor488-conjugate IgG (A-21206, Thermofisher, Milan, Italy), and donkey anti-mouse 
AlexaFluor594-conjugate IgG (A-27027, Thermofisher, Milan, Italy).
Protein sample preparation and immunoblotting. 1 mm slices of Ctrl and ALS ventral horn samples, 
were collected, cut into small pieces with a razor blade and immediately solubilized in 8 volumes of RIPA buffer 
(10 mM Tris-HCl, pH 7.4; 140 mM NaCl; 1% Triton X-100; 1% Na deoxycholate; 0.1% SDS; 1 mM Na3VO4; 1 mM 
NaF and 1 mM EDTA) added with a cocktail of protease inhibitors (Roche, Milan, Italy). The lysis was performed 
as previously described70. Briefly, on ice for 1 h and the samples were then centrifuged at 22,000xg for 1 h. The 
protein content of the supernatant was measured with a bicinchoninic acid (BCA) Protein Assay Kit (Rockford, 
IL, USA).
30 ug of protein samples were separated by 13% Tris-Glycine-SDS-PAGE and transferred to polyvinylidene 
difluoride membranes (Millipore, Milan, Italy) as described previously71. Membranes with blotted proteins were 
incubated with primary antibodies, washed, and incubated with peroxidase-conjugated secondary antibodies. 
Reactive proteins were revealed with an enhanced chemiluminescent detection system (ECL Plus; GE Healthcare, 
Buckinghamshire, UK) and visualized on a Versadoc imaging system (BioRad, Milan, Italy). Densitometry anal-
ysis was performed using Scion Image software (Frederick, MD, USA).
All data are reported as mean ± SEM. We used the Student’s t test for unpaired data and analysis of variance 
for multiple statistical comparisons between groups, the significance level being set at P < 0.05. The number of 
samples is indicated in the figure legend.
Immunofluorescence. Fresh sections of control and ALS spinal cord samples were rehydrated with PBS 
and fixed for 10 min with 4% paraformaldehyde in PBS (HT5014, Sigma, Milan Italy). Sections were washed 
in PBS and incubated with 1:200 diluted anti-SNAP25 and 1:1000 diluted anti-β3 tubulin or 1:200 diluted 
anti-Syntaxin-1A and 1:1000 diluted anti-β3 tubulin in 0.3% Triton X-100 in PBS overnight at 4 °C. After 
washings with PBS, sections were saturated with 0.1% Gelatin (Sigma, Milan, Italy) in PBS, and incubated 
with 1:1000 diluted AlexaFluor488 and AlexaFluor594 conjugated secondary antibodies for 1 hour at room 
temperature. After washings, sections were washed in PBS and mounted with Mowiol (Sima, Milan, Italy) and 
acquired using Leica TCS SP2 confocal microscope (Leica Microsystems, Heidelberg GmbH) for the quan-
titative analysis described in the next paragraph. Confocal 3D reconstruction was obtained using Leica TCS 
SP8 STED 3X and Leica HC PL APO 100x/1.40 Oil white objective with Type F Immersion liquid with 1.5 
refractive index (Pisani et al., 2016). Excitation of AlexaFluor488 and AlexaFluor594 dyes was performed with 
a continuous 488 nm and 594 nm wavelength diode laser with a maxim light output in focal plane of 10 mW 
(NKT Photonics sign supercontinuum laser). To obtain the confocal 3D projection, 30 planes were acquired 
in a Z-stack of 6–12 μm, and the series processed by Leica LASX software (Leica Microsystems, Mannheim, 
Germany).
Quantitative analysis of motor neuron size and SNAP25 and STX1A expression by immuno-
fluorescence in ventral horn sections. Single confocal planes of randomly chosen areas of ventral horn 
sections from three control donors and three ALS patients, stained as described above, were acquired by Leica 
TCS SP2 confocal microscope (Leica Microsystems, Heidelberg GmbH). Leica Confocal Software Version 2.61 
was used to measure motor neuron size and to quantify SNAP25 and STX1A expression levels. Motor neuron cell 
bodies were drawn based on the β3 tubulin staining, and the surface quantified and expressed in µm2. The average 
signal value relative to SNAP25 and STX1A for each motor neuron was also calculated and normalized on the 
motor neuron surface. Results were expressed as means ± standard error. Statistical significance was evaluated 
using unpaired Student’s t test. Difference with p < 0.05 were considered statistically significant.
Data availability. All sequencing data produced in the present work have been submitted to dbGaP database 
under the accession phs000747.
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